It is noteworthy that our results (Figures 2(c) and 2(d)) illustrate that in the HER2-overexpressing SKOV-3 (p53-null) cancer cells, PI3K/Akt signaling is dominantly activated as a result of increased HER2 activation and in the absence of p53, which has been reported to repress PI3K/Akt activity [20, 21]. Here, ERBB2 is linked to cancer.